Current status of glycoprotein IIB/IIIA receptor antagonists and evaluation of their molecular modeling.

ABSTRACT

Abciximab, Eptifibatide and Tirofiban are the three main glycoprotein IIb/IIIa receptor antagonists which have played a vital role in the field of cardiac medicine. They work by blocking the final mechanism of platelet aggregation pathway. These antagonists are widely used in treating acute coronary syndrome, myocardial infarction and during percutaneous coronary intervention (PCI). In this review, we have examined the chemistry, mechanism of action and clinical uses of these glycoprotein IIb/IIIa receptor antagonists. We also tried to study the binding mode of both eptifibatide and tirofiban with the glycoprotein IIb/IIIa receptors using molecular docking software. It appears that blocking the ASP 224 may be the cause for platelet activity inhibition.